Sign inJoin waitlistJoin the waitlist

CL

Charles Lopez

Professor of Medicine, School of Medicine · Oregon Health & Science University

Credentials: · · · ·

History

Oregon Health & Science University
Present

Medical oncology
1996–1998
University of California Medical Center
1991–1994
University of California San Francisco
Univ of California, San Francisco Sch of Med
1987–1991

Research

Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Science Advances · 2018 · 259 citations
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Review · Cellular and Molecular Gastroenterology and Hepatology · 2017 · 217 citations
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 2023 · 132 citations

AK
Adel Kardosh
21 papers
Skye Mayo
20 papers
EC
Emerson Chen
19 papers · 4 as a fellow
BS
Brett Sheppard
18 papers
TS
Thomas Sutton
13 papers · 10 as a resident
Kevin Billingsley
10 papers
BW
Brett Walker
9 papers · 6 as a resident
Gordon Mills
9 papers
NN
Nima Nabavizadeh
9 papers
GV
Gina Vaccaro
7 papers
LT
Liana Tsikitis
7 papers
Aaron Grossberg
6 papers

Grants

Mechanisms Linking ASPP2 to the Rb/E2F and p53 Pathways
National Cancer Institute · R01
Contact PI · $1.4M · Oregon Health & Science University
2004–2010
p53 and Uv Regulation of p53 Binding Protein Bbp/53bp2
National Cancer Institute · K08
Contact PI · $664.6K · Oregon Health & Science University
2000–2005

Clinical trials

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Recruiting · Early phase 1
OHSU Knight Cancer Institute
2026–2027
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Principal investigator · Terminated · Phase 2
OHSU Knight Cancer Institute
2025–2026
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Withdrawn · Phase 2
OHSU Knight Cancer Institute
2024–2027
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 1
OHSU Knight Cancer Institute
2022–2026